This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Valentine WJ, Goodall G, Townsend C, Kotchie R, Nielsen S, Erny-Albrecht K.Long-term economic outcomes associated with insulin aspart versus human bolus insulin in type 2 diabetes patients in the Swedish setting. Value in Health 10: A268-A269 (plus poster) abstr. PDB47, No. 6, Nov-Dec 2007
Erny-Albrecht K, Goodall G, Townsend C, Kotchie R, Nielsen S, Valentine WJ.Evaluating the long-term cost-effectiveness of insulin aspart (NovoRapid Rm) versus human soluble insulin in patients with type 2 diabetes in Spain and Italy. Value in Health 10: A260 (plus poster) abstr. PDB22, No. 6, Nov-Dec 2007
Rights and permissions
About this article
Cite this article
Insulin aspart and human insulin: a long-term economic comparison. Pharmacoecon. Outcomes News 540, 5 (2007). https://doi.org/10.2165/00151234-200705400-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200705400-00005